Orkin et al. “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy,” NIH Report and Recommendation, Dec. 7, 1995.* |
Marshall, E. “Gene Therapy's Growing Pains,” Science, vol. 269: 1050-1055, Aug. 25, 1995.* |
Mulligan, R.C. “The Basic Science of Gene Therapy,” Science, vol. 260: 926-932, May 14, 1993.* |
Miller et al., “Targeted vectors for Gene Therapy,” FASEB J., vol. 9: 190-199, Feb. 1995.* |
Verma et al., “Gene Therapy-Promises, Problems, and Prospects,” Nature, vol. 389: 239-242, Sep. 18, 1997.* |
Ulmer et al., “Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein,” Science, vol. 259: 1745-1748, Mar. 19, 1993.* |
Pedroza et al., “DNA Vaccination against Persistent Viral Infection,” J. of Virology, vol. 69: 2574-2582, Apr. 1995.* |
Kuzu et al., “In vivo priming effect during various stages of ontogeny of an influenza A virus nucleoprotein peptide,” Eur. J. Immunol., vol. 23: 1397-1400, Jun. 1993.* |
Bot et al., “DNA Immunization of Newborn Mice with a Plasmid-Expressing Nucleoprotein of Influenza Virus,” Viral Immunology, vol. 9: 207-210, Oct. 1996.* |
Bachmann et al, Current Opinion in Immunology, vol. 6:320-326, 1994.* |
Davis et al, “DNA-based immunization” Molecular and Cell Biology of Human Disease Series, vol. 5: 368-387, 1995.* |
Lai et al, “Use of the hepatitis B recombinant DNA yeast vaccine (H-B-Vax II) in children: two doses vs three doses of 5 micrograms regime; an interim report,” J. of Infection, vol. 13, Suppl. A: 19-25, Jul. 1986.* |
Lai et al. “Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs plasma-derived vaccine in children: immunogenicity and anamnestic responses,” Hepatology, vol. 18: 763-767, Oct. 1993.* |
Assateerawatt et al. “Immunogenicity and efficacy of a recombinant DNA hepatitis B vaccine, GenHevac B Pasteur in high risk neonates, school children and healthy adults,” vol. 11: 85-91, Jun. 1993.* |
del Canho et al. “Immunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccines in healthy neonates: a comparison of three different vaccination schemes,” vol. 41: 30-34, Sep. 1993.* |
Bot et al., 1996, J. Virol. 70: 5668-5672. |
Mor et al., 1996, J. Clin. Invest. 98: 2700-2705. |
Forstuber et al., 1996, Science 271: 1728-1730. |
Ridge et al., 1996, Science 271: 1723-1725. |
Sarzotti et al., 1996, Science 271: 1726-1725. |
Crowe, 1995, Vaccine 13: 415-421. |
Donnely et al., 1995, Nature Med. 1: 583-587. |
Justevicz et al., 1995, J. Virol. 19: 7712-7717. |
Martins et al., 1995, J. Virol. 69: 2574-2582. |
Donnelly et al., 1994, J. Immunol. Meth. 176: 145-152. |
Katsumi et al., 1994, Human Gene Therap. 5: 1335-1339. |
Ozaki et al., 1994, J. med Virol. 42: 47-51. |
Doherty 1993, Current Opin. Pediatrics 5: 3-13. |
Fynan et al., 1993, Proc. Natl. Acad. Sci USA 90: 11478-11483. |
Montgomery et al., 1993, DNA and Cell Biol. 12: 777-783. |
Taylor et al., 1986, Immunol. 58:417-420. |
Rubinstein et al., 1982, J. Exp. Med. 156:506-521. |